Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.42 |
| ▸ | AHCY | P23526 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2373109 | 0.98 | ADORA2A (0.49) | ADORA2AADORA1ADORA3AHCY | |
| SCHEMBL8606010 | 0.83 | SLC28A1 (0.53) | ADORA2AADORA1ADORA3AHCY | |
| SCHEMBL123719 | 0.81 | ADORA3 (0.49) | ADORA2AADORA1ADORA3AHCY | |
| SCHEMBL8608410 | 0.81 | SLC28A1 (0.53) | ADORA2AADORA1ADORA3AHCY | |
| SCHEMBL120550 | 0.78 | ADORA3 (0.51) | ADORA2AADORA1ADORA3AHCY | |
| SCHEMBL10689174 | 0.78 | ADORA3 (0.53) | ADORA2AADORA1ADORA3AHCY | |
| SCHEMBL8704526 | 0.78 | AHCY (0.47) | ADORA2AADORA1ADORA3AHCY | |
| SCHEMBL120561 | 0.77 | ADORA3 (0.50) | ADORA2AADORA1ADORA3AHCY | |
| SCHEMBL28822391 | 0.77 | ADORA3 (0.48) | ADORA2AADORA1ADORA3AHCY | |
| SCHEMBL11006064 | 0.77 | ADORA3 (0.48) | ADORA2AADORA1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501708-B2 | Adenosine compounds and their use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2013-08-06 | — | — | US | disclosed |
| EP-2552932-A1 | ADENOSINE COMPOUNDS AND THEIR USE THEREOF | Inotek Pharmaceuticals Corporation (US) | 2013-02-06 | — | — | EP | disclosed |
| US-20110245194-A1 | ADENOSINE COMPOUNDS AND THEIR USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2011-10-06 | — | — | US | disclosed |
| WO-2011119919-A1 | ADENOSINE COMPOUNDS AND THEIR USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245194-A1 | ADENOSINE COMPOUNDS AND THEIR USE THEREOF | ADORA1, ADORA2A, ADORA3 | ADORA2A 2/4885ADORA1 1/4885ADORA3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.